Join the Schizophrenia group to help and get support from people like you.
Schizophrenia News (Page 2)
Related terms: Catatonic Schizophrenia, Disorganized Schizophrenia, Paranoid Schizophrenia, Residual Schizophrenia, Schizophrenia, catatonic, Schizophrenia, disorganized, Schizophrenia, paranoid, Schizophrenia, residual, Schizophrenia, undifferentiated, Undifferentiated Schizophrenia
Transcranial Direct Current Stimulation Safe, Effective for Tardive Dyskinesia
MONDAY, Nov. 18, 2024 – Transcranial direct current stimulation (tDCS) may be an effective and safe treatment for improving the facial-oral motor symptoms of tardive dyskinesia (TD) in chronically...
FDA Approves Cobenfy for Adults With Schizophrenia
THURSDAY, Nov. 14, 2024 – The U.S. Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic agonist, for the treatment of schizophrenia in...
Psychedelics Like Psilocybin, MDMA Tied to Higher Odds for Schizophrenia
WEDNESDAY, Nov. 13, 2024 – People are at higher risk of schizophrenia if they indulge in psychedelic drugs, a new study warns. Patients who land in the ER following hallucinogen use have a 21-fold...
Childhood Attention Issues Show Links to Later Risk for Psychosis, Schizophrenia
TUESDAY, Oct. 29, 2024 – Most kids with attention issues won't go on to develop serious psychiatric conditions like psychosis or schizophrenia. However, a new study finds poor attention spans in...
Risk for Sudden Cardiac Death Elevated for Patients With Psychiatric Disorders
WEDNESDAY, Oct. 23, 2024 – Patients with psychiatric disorders have an increased rate of sudden cardiac death (SCD), according to a study published online Oct. 22 in Heart. Jasmin Mujkanovic, from...
High Rate of Comorbid Mental Health Disorders Seen in Schizophrenia
TUESDAY, Oct. 8, 2024 – Adults with schizophrenia spectrum disorders have high rates of comorbid mental health and substance use disorders, according to a study published online Sept. 23 in...
FDA Approves Cobenfy (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
PRINCETON, N.J.--(BUSINESS WIRE)--26 September 2024-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and...
FDA Approves Cobenfy, a New Kind of Drug for Schizophrenia
FRIDAY, Sept. 27, 2024 – The first new type of medication in decades to help fight against schizophrenia was approved on Thursday by the U.S. Food and Drug Administration. Cobenfy...
Most People With Schizophrenia Aren't Getting Treated
WEDNESDAY, Sept. 25, 2024 – Only 1 in every 4 U.S. adults struggling with schizophrenia receive "minimally adequate treatment," new data shows. Many of these patients also struggle with other mental...
Childhood BMI Linked to Increased Risk for Schizophrenia
MONDAY, Sept. 16, 2024 – Childhood body mass index (BMI) has a direct and enduring effect on the risk for schizophrenia later in life, according to a study published online Sept. 13 in Science...
Non-Substance-Related Mental Health Disorders Commonly Seen in Overdose Decedents
FRIDAY, Aug. 30, 2024 – More than one in five people who died of drug overdose in 2022 (21.9 percent) had a reported non-substance-related mental health disorder (MHD), according to research...
FDA Approves Erzofri (paliperidone palmitate) for the Treatment of Schizophrenia and Schizoaffective Disorder
PRINCETON, N.J., July 28, 2024 – Luye Pharma Group (Luye Pharma), an international pharmaceutical company dedicated to the R&D, manufacturing and sales of innovative medications, today announced that ...
Alterations in T Cell Subpopulations Linked to Brain Structure in Tardive Dyskinesia
THURSDAY, July 25, 2024 – Alterations in the proportion of T cell subpopulations are associated with brain structural abnormalities in patents with schizophrenia with tardive dyskinesia (TD),...
SNP rs13194504 AA Genotype Linked to Severity of Tardive Dyskinesia
TUESDAY, June 25, 2024 – For patients with schizophrenia, the single-nucleotide polymorphism (SNP) rs13194504 AA genotype is associated with reduced severity of tardive dyskinesia (TD), but is not...
SNP rs13194504 AA Genotype Linked to Severity of Tardive Dyskinesia
TUESDAY, June 25, 2024 – For patients with schizophrenia, the single-nucleotide polymorphism (SNP) rs13194504 AA genotype is associated with reduced severity of tardive dyskinesia (TD), but is not...
Further information
Related condition support groups
Related drug support groups
Seroquel, Abilify, Latuda, quetiapine, Vraylar, olanzapine, risperidone, Zyprexa, Risperdal, view more... aripiprazole, Seroquel XR, Rexulti, Geodon, Invega, Invega Sustenna